SHAREHOLDER ALERT: Brower Piven Announces an Investigation of Dynavax Technologies Corporation for P

Updated

SHAREHOLDER ALERT: Brower Piven Announces an Investigation of Dynavax Technologies Corporation for Potential Violations of the Federal Securities Laws

STEVENSON, Md.--(BUSINESS WIRE)-- Brower Piven, A Professional Corporation, has commenced an investigation of potential securities law violations by Dynavax Technologies Corporation ("Dynavax" or the "Company") (NasdaqCM: DVAX).

The investigation of Dynavax is related to positive statements issued by Dynavax concerning its investigational hepatitis B vaccine, Heplisav. On June 10, 2013, the Company disclosed that the U.S. Food and Drug Administration required additional data regarding the safety of Heplisav before it could further review the drug for potential approval. The price of Dynavax shares declined significantly following this news.


If you purchased Dynavax common stock between July 20, 2011 and June 10, 2013, the period during which Dynavax common stock may have been overvalued due to possibly misleading statements by the Company, and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.



Brower Piven, A Professional Corporation
Stevenson, Maryland
Charles J. Piven, 410-415-6616
hoffman@browerpiven.com

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS:

The article SHAREHOLDER ALERT: Brower Piven Announces an Investigation of Dynavax Technologies Corporation for Potential Violations of the Federal Securities Laws originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement